ARA-290 Side Effects: What the Cibinetide Trials Reported and What to Watch For

The medication this page covers:

The price is all-in: medication, physician review, refill management and shipping, with no membership fee. ARA-290 at Pepti is compounded by a PCAB-accredited, FDA-registered US 503A pharmacy. Compounded medications are not FDA approved, and ARA-290 has not been approved by the FDA or any other regulator.

Most compounded peptides have no human trials. ARA-290 has several randomised, double-blind, placebo-controlled phase 2 trials, all small, all short and all run by the group that designed it, plus two smaller studies. Every one of them looked at safety, which is where this page's information comes from.

Investigators across the trials, intravenous and subcutaneous, reported no safety concerns from clinical or laboratory assessments. That is a clean record, but it covers short courses in a few hundred people at most.

ARA-290 is an eleven-amino-acid peptide whose sequence was taken from one helix of erythropoietin, the hormone that tells bone marrow to make red blood cells. Erythropoietin itself had been studied for nerve, heart and kidney protection and kept hitting the same wall: at the doses needed, it thickens the blood and raises clotting risk.

ARA-290 was engineered to avoid that. It does not bind the erythropoietin receptor pair that drives red cell production, so it does not raise haemoglobin, and the trials confirmed no effect on blood counts. It is described as engaging only a second receptor assembly, which pairs one erythropoietin receptor with the beta-common receptor (CD131) and which the research group calls the innate repair receptor. The design purpose held up in the trials, so ARA-290 does not carry erythropoietin's clotting risk.

Because there is no interaction list, the intake asks for every medication and supplement you take, and a physician reviews it rather than a form.

Message your care team, through your account, if:

• Injection-site redness, swelling or soreness spreads, gets worse, or does not settle within a few days.
• You notice signs that could be low blood sugar, especially if you take insulin or another glucose-lowering medication. Treat it first, then report it.
• Any new symptom persists.
• You become pregnant or are planning a pregnancy.
• You start any new medication or supplement.
• Your label and your syringe seem not to match. Do not inject; ask first.

Do not change your own dose in response to a side effect, and do not take two doses to make up for a missed one. Your physician sets your directions after reviewing how you are doing, and any new directions are printed on the next label.

Call 911 or go to the nearest emergency department for:

• Swelling of the face, lips, tongue or throat.
• Trouble breathing or swallowing.
• A widespread rash or hives with feeling faint.
• Any reaction that is severe or spreading quickly.

If you think you injected far more than your directions, call Poison Control at 1-800-222-1222 and message your care team. Get emergency care first, then tell your physician.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. Athletes should read peptides for athletes and do peptides show up on a drug test.

As of the FDA's 14 May 2026 update, cibinetide (ARA-290) is in Category 3 of substances nominated for the 503A bulks list, "Bulk Drug Substances Nominated Without Adequate Support." That is a paperwork category, not a safety finding: the nomination lacked enough supporting information for the FDA to evaluate it. It is not on the Category 2 list of substances that raise significant safety risks, current as of 22 April 2026, and it was not among the peptides the Pharmacy Compounding Advisory Committee discussed in July 2026. It remains prescription-only and compounded.

ARA-290 has a cleaner and better documented safety record than most compounded peptides, because several randomised trials were run and none raised a safety concern. The design goal, no effect on red cell production, held up. The limits are real: the trials enrolled 22 to 64 people each, treatment mostly lasted four weeks, the developer ran them, and nothing is known about longer or repeated courses. A clean short-term record is also not evidence that the peptide does what it is prescribed for; the symptom questionnaires separated from placebo, but pain-intensity scores did not. The general guide is peptide side effects: what to watch for.

ARA-290 cannot be bought legitimately without a prescription. Products sold "for research use only" have no accountable pharmacy behind their identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
5. Your care team stays reachable for side effects and questions. Refills run every 28 days, one vial per fill.

Pepti is cash-pay and does not bill insurance, and prescribes ARA-290 in every state except Oklahoma, plus DC The dose arithmetic is in ARA-290 dosage.